Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Summary

This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic nasopharyngeal carcinoma.

Conditions

• Stage IV Nasopharyngeal Carcinoma

Interventions

DRUG

cisplatin and 5-Fu combined with nimotuzumab

DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks. Nimotuzumab 200mg/d, intravenous infusion every week

Sponsors & Collaborators

• Fujian Cancer Hospital

  collaborator OTHER_GOV

• First People's Hospital of Foshan

  collaborator OTHER

• People's Hospital of Guangxi Zhuang Autonomous Region

  collaborator OTHER

• Guangxi Medical University

  collaborator OTHER

• Guangzhou Medical University

  collaborator OTHER

• Hubei Cancer Hospital

  collaborator OTHER

• Hunan Provincial Cancer Hospital

  collaborator UNKNOWN

• Hangzhou Cancer Hospital

  collaborator OTHER

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Jiangxi Provincial Cancer Hospital

  collaborator OTHER

• Affiliated Cancer Hospital of Shantou University Medical College

  collaborator OTHER

• Wuhan University

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Sun Yat-sen University

  lead OTHER

Principal Investigators

• Chong Zhao, MD · Sun Yat-sen University

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-05-31

Primary Completion

2015-07-31

Completion

2015-07-31

Countries

• China

Study Locations